text:
November 24, 2014
WHITE SULPHUR SPRINGS, W.Va. (AP) -- Three-time champion Tim Fisher has been disqualified from this year's West Virginia Amateur.
West Virginia Golf Association Executive Director Ken Tackett says Fisher played the wrong ball on the 12th hole of the Old White TPC Course in Monday's first round.
Fisher hit his tee shot toward some trees and finished the hole using a provisional ball, even though the first one was eventually found. Tackett says Fisher was disqualified because the error wasn't corrected before he teed off on the next hole.
Fisher was coming off a three-year suspension in WVGA events. He was suspended one year for failing to give proper notification when he pulled out of a 2010 tournament in North Carolina. He got a two-year suspension in 2011 for an undisclosed code of conduct violation.
Click Here to access the online Public Inspection File
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or firstname.lastname@example.com.


text:
Most Music Mornings
Listen Live
Listen on Your Phone
Audio Vault
Photo Gallery
Ron Olson
Michelle Lewis
Sheryl Stewart
Chris Michaels
Screwy News
Daily Dish
Trending Now
Sheryl Stewart
Author & Filmmaker, Bill Carter
by Sheryl Stewart
posted Feb 24 2011 7:13PM
If you're looking for something to do this weekend, it doesn't get much cooler than good food & good conversation for a great cause. Internationally known author and filmmaker, Bill Carter, is going to be in Astoria for the annual
Fisherpoets gathering
. Bill will be reading from his memoir, "Red Summer", as well as showing a film based on the book. He will also be a celebrity bartender at Clemente's to raise awareness and money to help save the salmon, environment, and way of life in Bristol Bay, Alaska.
Here's a link for more info.
I talked to Bill about his film, "MIss Sarajevo", as well as his relationship with Bono & U2, his passion for saving Bristol Bay, and his next project.
Listen below.
bill carter edit
Find out more about Bill at his website, www.billcarter.cc
Back To Blog
Author & Filmmaker, Bill Carter
Please Enter Your Comments Below
Great interview, Sheryl! Have fun at the Fisher Poets... I loved it last year.
Title :
Comment :
Please enter the text as it is shown in the box below :
Refresh Image
Download the FM100 iPhone App
Connect to FM100 / Facebook & Twitter
A Moment For Your Health
advertise with us
Recent Blog Posts
What Every Celebrity's Commercial Pretty Much Sounds Like!
Michelle Lewis
Nov 28
Insensitive or Sincere?
Mike Stanz
Nov 28
Um, Bette, Say What?
Mike Stanz
Nov 28
No Thanksgiving for You!
Mike Stanz
Nov 28
The Force Awakens Slowly
Mike Stanz
Nov 28
Things You Didn't Know About Yesterday
Mike Stanz
Nov 28
"I See a Darkness in You"
Mike Stanz
Nov 28
Bye Bye Clydesdales?
Mike Stanz
Nov 28
Artist Interviews
Buzz-worthy News
Crazy News Quiz
New Music
Sheryl Stewart
What To Do This Weekend
Nov 2014
Oct 2014
Sep 2014
Aug 2014
Jul 2014
Jun 2014

subset: commoncrawl


text:
Report abuse
Bsnl Rohtak Customer Care Phone Number
: 18001801503, 01262 256 222
What was the response after calling on this number ?
To write click here.
Bsnl Rohtak
BSNL is the leading telecommunication company in India. BSNL is the largest and oldest operating firm well known for its quality of work in India. The company facilitates in land line, mobile telephony, internet service, digitization and IPTV. The company has recruited talented employees. BSNL is a government owned telecommunication company. BSNL is the largest provider of fixed telephony and 3G services as per the number of subscriber. The company is the main leader in providing internet broadband service. These includes all major Indian states. The postal and official address, email address and phone number (helpline) of Bsnl Rohtak service center and Bsnl Rohtak customer care number is given below. The helpline of Bsnl Rohtak customer care number may or may not be toll free. The contact detail like customer care phone number of Bsnl Rohtak is 18001801503, 01262 256 222 and the address means physical operational location of Bsnl Rohtak customer care number is Church Road, Rohtak, Haryana 124001, India. The website www.bsnl.co.in where you can get more detail about Bsnl Rohtak customer care number.
If the contact information is incorrect, please let us know
Is your problem solved after calling ?
Your Complaint
Complaint :
Your Name :
Email Address :
Gender :
Image Text :
Allcustomercarenumbers.com Advertisements
Keep in Touch With Us
Share this page on facebook :
Related Search
Philips Rohtak Customer Care Number
Bsnl Madhya Pradesh Customer Care Number
Bsnl Maharashtra Customer Care Number
Bsnl Ludhiana Customer Care Number
Bsnl Chennai Customer Care Number
Bsnl Lucknow Customer Care Number
Bsnl Kumbakonam Customer Care Number
Bsnl Kukatpally Customer Care Number
Bsnl Kurukshetra Customer Care Number
Bsnl Kurnool Customer Care Number
Bsnl Kozhikode Customer Care Number
Bsnl Kota Customer Care Number
Bsnl Kottayam Customer Care Number
Bsnl Mobile Kolkata Customer Care Number
Bsnl Alappuzha Customer Care Number
Bsnl Ajmer Customer Care Number
Bsnl Ahmedabad Customer Care Number
Bsnl Landline Ahmedabad Customer Care Number
Bsnl Evdo Ahmedabad Customer Care Number
Bsnl Agra Customer Care Number
Bsnl Rohtak Customer Care Number Complaints and Reviews
Mr. anil Says
May 15, 2013
telephone number 251446 installed at araya Nagar,rohtak in name of senior citizen not functioning sice last two monts and the complaints of the saame are also not being attended and this is gross deficiency i service and harassment
Mr. param Says
Jul 03, 2013
Dear sir, i have BSNL broadband connection. My broadband stops work since 15 days.i had complain to BSNL exchange, but nobody hear about my complain. sir, anybody help me and resolve my broadband problem.i am very upset. Please repair my internet connection otherwise i change my i disconnect my c
onnection because when BSNL does not provide service to me then why should i pay to him.
Mr. Pardeep Says
Oct 12, 2013
Dear sir,our landline phone has been out of order from last five days and its a broadband connection.I am requesting you to correct the phone.ASAP.
Tel.ph. no.-01262-255700.
Total power solutions, sonepat road rohtak
Mr. nitin Says
Oct 16, 2013
dear sir,i have broadband connection.my broadband is not working since 20days. i had complain to BSNL exchange
many times, but nobody hear my complain. sir please resolve my problem otherwwise i will disconnect the connection .
Mr. Jagjit Singh Malik Says
Feb 14, 2014
My telephone number 01262-245893 has been temporarily disconnected for non payment of bill. However my outstanding was rupees 852 and pay by date was 24 -2-2014 and i have paid the same also. I fail to understand why my line has been disconnected. Kindly look into the matter and restore immediately.
Mr. Akhil Says
Apr 12, 2014
My broadbrand is not working for last seven days my number is 01262-255375.
Mr. Sanjay Manocha Says
Jun 30, 2014
Our BSNL landline number -01262-258436 is not working. Please do the needful as early as possible.
Ms. Manisha Says
Sep 13, 2014
My BSNL landline is not working.
My landline no 01262-278150.
491/33 naya parav kath mandi rohtak.
Mr. Vinay Says
Oct 09, 2014
I have applied for a broadband connection more than a month ago, but haven't got yet. Whenever i consult the staff, they simply dump on me a variety of phone number to ring about, no one to solve the problem.
Mr. Krishan Kumar Says
Nov 07, 2014
The problem has not been solved after many times of registered complaint on 198. I have not four times registered. Before 20 days your lineman has come and gone without solve this problem. my telephone number is 01262-213182 model town Rohtak.
Copyright © 2014 allcustomercarenumbers.com. All rights reserved.
About Us
Privacy Policy
Contact Us


text:
Originally posted 10/21/2014 01:30PM
Hungry Girl lightens up his royal highness's go-to comfort food: cottage pie
Originally posted 10/20/2014 06:30AM
It will be a very special wedding anniversary for Prince William and Kate next April.
Originally posted 10/13/2014 09:00PM
In 1974, PEOPLE magazine released its inaugural issue, featuring Mia Farrow as the cover star.
Originally posted 10/10/2014 02:15PM
It's time to settle this, once and for all.
Originally posted 10/10/2014 07:30AM
Princess Kate is set to return to public duties.
Originally posted 10/08/2014 08:20AM
The Duchess of Cambridge has quietly pulled out of another engagement because of her ongoing severe pregnancy sickness.
Originally posted 10/07/2014 12:10PM
The Duchess of Cambridge has been getting some home comforts as she continues to battle the effects of severe pregnancy sickness.
Originally posted 10/06/2014 03:55PM
Prince William is planning to make an official visit to New York in the coming months, PEOPLE has learned.
Originally posted 10/03/2014 03:15PM
With a lively 14-month-old son and a wife suffering from severe morning sickness during her second pregnancy, Prince William can use all the support he can get.
Originally posted 09/29/2014 08:45AM
Bump watchers, get ready: Princess Kate is planning her return to royal duties over the next month.
Top 10 News Categories
The most buzzed about stars this minute!
Treat Yourself! 4 Preview Issues
More On PEOPLE.com
Got a News Tip?
Send it to our People.com editors!
News Archive


text:
You may notice more cyclists sharing the streets of Honolulu these days.
The dinos are back, and this time they've got Star-Lord to contend with.
No email address was supplied by
To complete your registration on this site, please supply an address.
Please confirm or modify the email address to which you will have subscription offers sent.
For a more personalized experience, please supply the following optional information.


text:
Last we saw Gameboi, on an early-August premiere off his latest mixtape, he was standing on Top of the World alongside reader faves XV and Jon Connor. Of course, he wasn't about to stop there; on this freshly-minted project standout, the Ann Arbor spitter's Rise to prominence continues, taking him straight through the Earth's atmosphere into the loftiest heights of lyrical excellence. With Alex Goose's infectious sample work banging in the back, the artist flies lyrical circles around the competition, delivering agile bars packed with witty punchlines and pop-culture references. Motown emcees Ro Spit and One Be Lo follow the headliner's opening verse with equally fresh, exuberant middle and closing 16s. Craving more bangers from this teenage microphone fiend? Then do yourself a favor and cop Young and Restless, available free of charge from the artist's Bandcamp.
Isaac CastorRo Spit One Be Lo Downloads
Written by richard on 09/24/12
Submit your Rating
First DJ Booth Appearance:
"Act Right" (2011)
You Might Like...
Commentsblog comments powered by Disqus
- Beyond the Lights: Machine Gun Kelly Learns to Act Like Himself
- Reggie Bonds - Stream of Consciousness Pt. 1
- Eminem Vs. DJ Whoo Kid - Shady Classics
- Kid Cudi Thinks Hip-Hop Is Endangered - He's Wrong
- Tayyib Ali - Keystone State of Mind III
- 10 Must Have Hip-Hop Downloads of the Week (11/21)
- What Rappers Would You Pick for "New York vs. Everybody"?
- Your Favorite Indie Rapper is Secretly Signed to a Major Label
- The DJBooth - Top Prospects EP (Vol. 2)
- The Best Hip-Hop & R&B Songs of 2014 (Ongoing)
DJBooth TV
Discover the best new songs, videos, and albums added to the Booth.


text:
|By PlatformPCPS3Xbox 360Wii U3DSPS VitaAndroidiPhoneiPadOther HardwareEditor's Choiceby Author
|By LatestThe best and worst s : May Returns Tales from the Borderlands: Zer0...
9.0Geometry Wars 3: Dimensions
10.0Persona Q: Shadow of the Labyrinth
8.5Sneaky Sneaky
5.0Logitech G910 Orion Spark Sonic Boom: Shattered Crystal
5.0Sonic Boom: Rise of Lyric
5.0Super Smash Bros. for Wii U
9.5LittleBigPlanet 3
7.5More reviews
|By GenreActionAdventureFightersFree-to-playMMOMusicPlatformShootersSportsRPGStrategyMore genres
[Update: The show is over! Check below for a recap of all the winners. We'll be posting clips of the show as they become available. The 16th Annual D.I.C.E. Awards are live tonight, and will be starting at any moment. These ...
|Hamza CTZ Aziz
Gearbox Software president Randy Pitchford's D.I.C.E. Summit presentation focused on how player choice is a good thing for games. In one of his many examples on how choice works in games like Borderlands 2, he touched on a bit of psychology, using the work of Harvard psychology professor Dan Gilbert to show that the choices players make become the 'best' choice.
|Dale North
Jenova Chen admitted to being "a nerdy guy that likes to stay at home" during his D.I.C.E. Summit 2013 talk on Journey, but he still wanted to connect with others, and hoped he could do so in MMOs like World of Warcraft. But ...
|Dale North
Jenova Chen's D.I.C.E. Summit talk on my favorite game of last year, Journey, was moving for many reasons, but I was particularly moved when I heard that his team, thatgamecompany, went bankrupt in the struggle to finish the game.
After the allotted two years in development, Journey still wasn't there. It wasn't meeting the emotional peaks and valleys they had hoped to hit. This left them with a rough choice -- ship the game as is, or go back into it to make it as emotionally moving as they had originally hoped it would be.view full story + comments
thatgamecompany's Jenova Chen shared this fan letter during his D.I.C.E. Summit 2013 presentation today on his team's journey making Journey. Your game practically changed my life. It was the most fun I had with him since he...
|Dale North
Pull up a chair, sit down, and listen to Valve co-founder Gabe Newell's D.I.C.E. keynote that was given today in Las Vegas. If you missed the talk as it happened live earlier this morning, Variety has got your back with reco...
|Jordan Devore
Speaking at the 2013 D.I.C.E. Summit today, designer Warren Spector took on the concept of how gaming content has changed over time, how tastes may change as you age, and how developers need to address those changes. To stres...
|Chris Carter
As you may have heard, Junction Point recently closed. Studio head Warren Spector just ended his D.I.C.E. 2013 Summit talk this morning with a reminder of that, for all his peers at the event. The audience had a laugh. Someone hire this man!
|Dale North
Valve's Gabe Newell gave us his thoughts on cloud gaming this morning at his D.I.C.E. Summit keynote, saying that he's a skeptic of the technology. While he backs in-home streaming as a solution for getting PC games on living...
|Dale North
At Valve boss Gabe Newell's D.I.C.E. Summit keynote this morning, he ran down what he feels are three separate but complementary segments for PCs in the living room. Valve believes that the openness of the internet and PCs are what's best for the gaming industry. PCs in the living room will be key for getting away from what he calls the "disruptive console cycle."
|Dale North
The Android isn't the only thing Ouya's borrowing from the mobile market -- the swift obsoletion of hardware is apparently high up on Ouya's checklist, too! According to CEO Julie Uhrman, a new console is being planned f...
|Jim Sterling
With videogames being everywhere and on everything, OUYA CEO Julie Uhrman took the stage at D.I.C.E. Summit 2013 to remind us how much we love the television. She believes that the big screen in the center of our home is wher...
|Dale North
Where do all the devs and industry types go between sessions and meetings here at D.I.C.E.? They go to Bar+Cade, the event's official hangout. It's a large, circular bar, stocked full with drinks, surrounded by everything you...
|Dale North
The importance of quality software for the upcoming OUYA has been harped on for months, but at least in the short term, it sure does look like this console will be successful. Following the news that OUYA will be sold at reta...
|Jordan Devore
Coming back from lunch here at D.I.C.E. Summit 2013, I ran into an event staffer with the greatest arm tat I've ever seen. You see a lot of tattoos in Las Vegas, but I've never seen one that stopped me dead in my tracks. "Is ...
|Dale North
During David Cage's presentation at D.I.C.E. Summit 2013 this morning, in a talk on his vision for the game industry, he addressed last year's E3's showing of violent, shocking content. The Quantic Dream boss made it clear th...
|Dale North


text:
30 results was found matching keyword
0 vote(s)Comment
Báo Thanh Niên English 2 day(s) ago
Vietnam Airline fined two female passengers VND 7.5 million ($350) each for causing a scene over a male passenger on a Friday night flight from Ho Chi Minh City to Hanoi.
Keywords: manallegedlyquarrelquellA MemberPassengersLovers
Báo điện tử CP English 6 day(s) ago
2 related news
VGP – PM Nguyen Tan Dung has approved the construction of an international passenger ship port in Phu Quoc Island in the southern province of Kien Giang.
Keywords: justifyPhu QuocShipscruisePm Nguyen Tan DungPhu Quoc IslandProvincial People
Báo Thanh Niên English 5 day(s) ago
Vietnam's aviation authorities suspended a technician and a senior air traffic controller at Tan Son Nhat Airport on Thursday afternoon for a blackout that affected more than ten flights.
Keywords: FlightsTan Son Nhat AirportVietjet AirPassengersarriveTan Son Nhat
Vietnam has finally cracked down on its famously precarious tourism boat industry.
Keywords: BoatsVung Taudecreeboatboundshallowfire
VietnamNet English 6 day(s) ago
VietNamNet Bridge – The Railway Administration has asked the Ministry of Transport's appraisal and approval of a $10 billion plan to modernize the North-South railway.
Keywords: North SouthtransportspeedRailwaysHanoi HcmcGoodsSaigon
Báo Tuổi Trẻ English 6 day(s) ago
Vietnamese Prime Minister Nguyen Tan Dung has agreed in principle to a project to set up an international passenger port on Phu Quoc Island in the southern province of Kien Giang.
Keywords: Kien GiangPhu QuocPhu Quoc IslandpropositiondocumentPrime Minister Dungproject
Báo Tuổi Trẻ English 1 week(s) ago
2 related news
Railway passengers in Hanoi and Ho Chi Minh City who have booked tickets and paid for them online can have their tickets delivered to their home for free at their request as of next month, the Vietnam Railways Corporation (VRC) has said.
Keywords: TicketsPassengersOnlinerequestbookhome
Báo Dân Trí English 1 week(s) ago
2 related news
The Vietnam Railway Corporation (VNR) will sell tickets online starting December 1.
Keywords: TicketsPassengersOnlineThe Vietnam Railway Corporationtransportfreightbuy
Báo Đầu Tư English 1 week(s) ago
1 related news
The Viet Nam Railway Corporation (VNR) will sell tickets online starting December 1.
Keywords: TicketsPassengersOnlinetransportfreightbuystation
VietNam News English 1 week(s) ago
1 related news
Báo Thanh Niên English 3 week(s) ago
A local transport company recently purchased a batch of high-quality passenger vehicles to ferry tourists from Ho Chi Minh City to the beach city of Vung Tau.
Keywords: Vung TauTransport Companydepartcell phonetransitcomfortferry
VietnamNet English 1 week(s) ago
VietNamNet Bridge – Le Thi Hong Hanh rushes out of her house at 5 am, hops on her old motorbike and heads for the bus station in HCM City's District 4. Once there, she gives her 30-seat passenger bus a quick inspection and then jumps into the cabin and starts the engine.
Keywords: DriversdrivePassengersmotorbikestationBen Thanh Marketwheel
Báo Tuổi Trẻ English 2 week(s) ago
Flights have helped air hostesses and their male colleagues and regular passengers become couples, but they have also led husbands and wives to being separated thanks to the distance and lack of time.
Keywords: FlightsAttendantsThu HaEach Otherletterby chanceTan Son Nhat International Airport
VietnamNet English 2 week(s) ago 3 duplicate news
As many as 1,608 investors, including 28 international investors and two Vietnamese organisations, have registered to buy shares in the national flag carrier Vietnam Airlines at its initial public offering scheduled for November 14.
Keywords: Vietnam AirlinesbuySkyteamOrganisationsEmployingconveneTwo Vietnamese
Báo Thanh Niên English 2 week(s) ago
1 related news
On a rainy Ho Chi Minh City night, a half dozen ground handlers in reflective vests grunt and yell as they jockey an aluminum container onto the main deck of an Airbus A320 cargo jet bound for Hong Kong.
Keywords: Tan Son Nhat International AirportfreightSamsungOn NovAirlinesExportsShipments
Top page
| Sign up |
Forgot password
News collection and classification on Baomoi were automatically processed by a computer program.
Publication permit No. 46/GP-TTĐT, Ministry of Information and Communications.
Copyright © by EPI Join Stock Company. All rights reserved.


text:
Monoclonal IgM antibodies which promote central nervous system remyelination when given to a mammal afflicted with a demyelinating disease are disclosed. These antibodies show multi-organ autoreactivity, and recognize both surface and cytoplasmic determinants on glial cells.
1. A monoclonal antibody capable of stimulating remyelination of central nervous system axons, said monoclonal antibody produced by the hybridoma having the ATCC accession No. CRL 11627.
2. A hybridoma consisting of hybridoma ATCC accession No. CRL 11627 that produces a monoclonal antibody capable of stimulating remyelination of central nervous system axons.
The invention described herein was supported in whole or in part by the National Institutes of Health, Grant No. NS-24180 and the National Multiple Sclerosis Society Grant No. RG-1878-B-2. The United States Government has certain rights in the invention.
Multiple sclerosis (MS) is a chronic, frequently progressive, inflammatory central nervous system (CNS) disease characterized pathologically by primary demyelination, usually without initial axonal injury. The etiology and pathogenesis of MS are unknown. Several immunological features of MS, and its moderate association with certain major histocompatibility complex alleles, has prompted the speculation that MS is an immune-mediated disease (Hafler, D. A. and Weiner, H. L., Immunol. Today, 10:104-107 (1989); Compston, D. A. S., "Genetic susceptibility to multiple sclerosis," In: McAlpine's Mutiple Sclerosis (Matthews, B. ed), pp 301-319, London: Churchil Livingstone (1991); Olsson, T., Curr. Opin. Neurol. Neurosurg,, 5:195-202 (1992)).
An autoimmune hypothesis is supported by the experimental autoimmune (allergic) encephalomyelitis (EAE) model, where injection of certain myelin components into genetically susceptible animals leads to T cell-mediated CNS demyelination (Kabat, E. A. et al., J. Exp. Med., 85:117-129 (1947); Lublin, F. D., Spinger Semin. Immunopathol., 8:197-208 (1985)). However, specific autoantigens and pathogenic myelin-reactive T cells have not been definitively identified in the CNS of MS patients, nor is MS associated with other autoimmune diseases. An alternative hypothesis, based upon epidemiological data (Martyn, C., "The epidemiology of multiple sclerosis. In: McAlpine's Multiple Sclerosis, (Matthews, B. ed), pp 3-40, London: Churchil Livingstone (1991) is that an environmental factor, perhaps an unidentified virus, precipitates an inflammatory response in the CNS, which leads to either direct or indirect ("bystander") myelin destruction, potentially with an induced autoimmune component (Lampert, P. W., Am. J. Path. 91:176-208 (1978)). This hypothesis is supported by evidence that several naturally occurring viral infections, both in humans (Rice, G. P. A., Curr. Opin. Neurol. Neurosurg., 5:188-194 (1992)) and animals (Dal Canto, M. C. and Rabinowitz, S. G., Ann. Neurol., 11:109-127 (1982)), can cause demyelination. One commonly utilized experimental viral model is induced by Theiler's murine encephalomyelitis virus (TMEV) (Dal Canto, M. C., and Lipton, H. L., Am. J. Path., 88:497-500 (1977)).
The limited efficacy of current therapies for MS and other demyelinating diseases (Goodkin, D. E. et al., Clev. Clin. J. Med., 59:63-74 (1992)), has stimulated interest in novel therapies to ameliorate these diseases (Martin, R., et al., Ann. Rev. Immunol., 10:153-187 (1992); Steinman, L., Adv. Immunol., 49:357-379 (1992); Weiner, H. L., et al., science 259:1321-1324 (1993)). However, due to the apparently complex etiopathogenesis of these diseases, potentially involving both environmental and autoimmune factors, the need still exists for an effective treatment of these demyelinating disorders.
The present invention relates to the promotion, or stimulation, of remyelination of central nervous system axons in a mammal. Specifically, the present invention relates to methods of stimulating the remyelination of central nervous system (CNS) axons using a monoclonal antibody obtained from a mammal-immunized with spinal cord homogenate (SCH) from a normal mammal (i.e., uninfected with any demyelinating disease). This monoclonal (mAb) is referred to herein as SCH94.03,and the hybridoma producing this monoclonal antibody has been deposited on Apr. 28, 1994, under the terms of the Budapest Treaty, with the American Type Culture Collection (ATCC) and given ATCC Accession No. CRL 11627. As demonstrated herein, treatment of a mammal afflicted with a demyelinating disease using the mAb, SCH94.03, resulted in an increase in CNS remyelination compared to mice treated with control mAb.
The present invention also relates to methods of treating demyelinating diseases in mammals, such as multiple sclerosis in humans, and viral diseases of the central nervous system of humans and domestic animals, such as post-infectious encephalomyelitis, or prophyiactly inhibiting the initiation or progression of demyelination in these disease states, using the SCH94.03 monoclonal antibody. This invention further relates to in vitro methods of producing, and stimulating the proliferation of, glial cells, such as oligodendrocytes, and the use of these glial cells to treat demyelinating diseases.
FIG. 1 is a graph depicting the dose-response characteristics of antibody-mediated proliferation of cells in mixed rat brain culture.
FIG. 2 is a graph depicting the temporal profile of antibody-mediated proliferation of cells in mixed rat brain culture.
FIG. 3A-3D shows light and electron micrographs of CNS remyelination promoted by mAb SCH94.03. FIG. 3(A) Light micrograph of spinal cord section from a chronically infected SJL/J mouse treated with SCH94.03 showing CNS remyelination. FIG. 3(B) Light micrograph of spinal cord section from a chronically infected SJL/J mouse treated with a control IgM showing extensive demyelination, and the relative absence of remyelination. Inflammatory cells, including macrophages with ingested myelin debris are indicated by arrows. The asterisk indicates a representative naked axon. FIG. 3(C) Light micrograph of spinal cord section with normal myelin. FIG. 3(D) Electron micrograph of spinal cord section from an animal treated with SCH94.03 showing multiple axons with abnormally thin myelin sheaths relative to axon diameter. The star in the upper right-hand corner indicates an axon with normal myelin sheath thickness. Arrowheads point to astrocytic processes, which are intimately associated with remyelinated axons. Scale bars represent 13 μm in A-C, and 2 μm in D.
FIG. 4 is a graph depicting the correlation between the change in clinical disease and morphological remyelination.
FIG. 5 is a graph depicting the dose-response relationship between treatment with mAb SCH94.03 and CNS remyelination. Area of CNS remyelination () and percentage of lesion area with remyelination (∘) in animals treated with various doses of mAb SCH94.03.
FIG. 6 shows a Western blot of TMEV proteins. Lysates from infected L2 fibroblast cells were separated by SDS-PAGE, transferred to nitrocellulose, and blotted with SCH94.03 (lane 1), SCH94.32 (lane 2), serum from susceptible mice chronically infected with TMEV (lane 3), and polyclonal rabbit anti-TMEV IgG (lane 4). Molecular weights are indicated on the left in kilodaltons (kDa). The position and identification of the major TMEV capsid proteins are indicated on the right.
FIGS. 7A-7D show the immunostaining of cultured glial cells (FIGS. 7A and 7B) and frozen CNS tissue sections (FIGS. 7C and 7D) with mAb SCH94.03. Scale bars represent 15 μm.
FIGS. 8A-8C shows the results of SCH94.03 (FIG. 8A) and control IgMs (FIG. 8B and 8C) binding to protein antigens as determined by ELISA.
FIG. 9 shows the results of SCH94.03 F(ab2)' binding to protein antigens as determined by ELISA.
FIGS. 10A-10C show the results of SCH94.03 (FIG. 10A) and control IgMs (FIG. 10B and 10C) binding to chemical haptens as determined by ELISA,
FIGS. 11A14 11F show the alignment of the immunoglobulin light and heavy chain variable region sequences of SCH94.03 and control IgM, CH12, and germline Ig gene segments (SEQ ID NOS: 1-11).
The present invention relates to the promotion, or stimulation, of remyelination of central nervous system axons in a mammal. Specifically, the present invention relates to methods of stimulating the remyelination of central nervous system (CNS) axons using a monoclonal antibody obtained from a mammal immunized with spinal cord homogenate from a normal mammal (i.e., uninfected with any demyelinating disease). The antigen reactivity of the monoclonal antibody, an IgM monoclonal antibody referred to herein as SCH94.03 (also referred to herein as SCH94.32) has been characterized as described in the present invention using several biochemical and molecular assays, including immunohistochemistry, immunocytochemistry, Western blotting, solid-phase enzyme-linked immunosorbant assays (ELISA), and Ig variable region sequencing. The hybridoma producing monoclonal antibody SCH94.03 has been deposited on Apr. 28, 1994, under the terms of the Budapest Treaty, with the American Type Culture collection (ATCC) 12301 Parklawn Drive, Rockville, Md. 20852-1776, and has been given ATCC Accession No. CRL 11627. All restrictions upon the availability of the deposit material will be irrevocably removed upon granting of the patent.
The present invention also relates to methods of treating demyelinating diseases in mammals, such as multiple sclerosis in humans, and viral diseases of the central nervous system of humans and domestic animals, such as post-infectious encephalomyelitis, using the SCH94.03 monoclonal antibody. Methods of prophylactic treatment using the mAb to inhibit the initiation or progression of demyelinating diseases are also encompassed by this invention.
A panel of monoclonal antibodies (mAbs) derived from splenocytes of uninfected SJL/J mice injected with SCH was constructed as described in detail in Example 1. After the initial fusion and cloning, 2 of the 95 wells with viable Ig-secreting hybridomas contained mAb with significant binding to SCH as demonstrated by ELISA. Hybridoma cells from these two wells, called the 79 and 94 series, were subcloned by limiting dilution and screened again for binding to SCH by ELISA. For the 79 series hybridomas, 14 out of 49 clones were positive by SCH ELISA, while for the 94 series, 17 out of 32 were positive for binding to SCH. Based upon the ELISA data, two 79 series hybridomas (SCH79.08 and SCH79.27), both of which also reacted with myelin basic protein (MBP) by ELISA, and three 94 series hybridomas (SCH94.03, SCH94.11, and SCH94.32), none of which reacted with MBP, were chosen for ascites production and in vivo transfer experiments.
As described in Example 2, the mAbs were tested for their ability to promote proliferation of glial cells in vitro. As shown in Table 1, rat optic nerve cells grown in the presence of mAb 94.02 or 79.27 incorporated more [3H]thymidine than controls grown in media alone or with an isotype-matched control mAb. Data is shown from one of five experiments which showed a similar result.
TABLE 1__________________________________________________________________________Monoclonal Antibodies to Spinal Cord Homogenate PromoteIncorporation of [3 H]Thymidine in Cultured Optic Nerve Glial Cells Stimulation IndexAdditive CPM Mean + Isotype Stimulationin Medium μg/ml SE Control P Index PBS P__________________________________________________________________________mAb 94.32 3 3,642 � 364 2.68 <0.01 2.17 <0.01mAb 79.27 3 2,326 � 182 1.71 <0.01 1.38 <0.05Isotype 3 1,359 � 82 1.00 -- 0.81 --ControlPBS -- 1,680 � 203 1.23 -- 1.00 --mAb 94.32 10 4,663 � 114 2.78 <0.002 1.90 <0.01mAb 79.27 10 2,711 � 176 1.62 NS 1.11 NSIsotype 10 1,678 � 213 1.00 -- 0.68 --ControlPBS -- 2,451 � 946 1.46 -- 1.00 --mAb 94.32 30 3,855 � 639 4.01 <0.03 2.44 <0.002mAb 79.27 30 4,037 � 371 4.20 <0.04 2.56 <0.003Isotype 30 962 � 191 1.00 -- 0.61 --ControlPBS -- 1,578 � 231 1.64 -- 1.00 --__________________________________________________________________________
The dose-response characterisitcs of antibody-mediated proliferation were then examined. As shown in FIG. 1, maximal stimulation with 94.03 was seen at 100 ng/ml. Control myeloma IgMs MOPC 104E and TEPC 183 (data not shown) also stimulated the mixed rat brain cultures to proliferate. However, the maximal effect was seen at a 10-fold higher concentration than that seen with the mAbs.
The temporal profile of antibody-mediated proliferation was also examined as shown in FIG. 2. On day 8, after culture initiation, 100 ng/ml antibody was added to the cultures (time 0). Cells were harvested at 24 hour intervals; [3 H]thymidine was present for the final 24 hours of culture to measure the total proliferation during the interval. The maximal stimulation with 94.03 was seen at 72 hours after antibody addition. Similar results were obtained with 94.32. None of the isotype control antibodies showed any significant proliferation throughout the 120 hours of culture. These data demonstrates that both mAbs 94.32 and 94.03 induce proliferation of glial cells of mixed rat brain culture. This proliferation is maximal at an antibody concentration of 100 ng/ml and a culture period of 72 hours after antibody addition.
As described in Example 3,SJL/J mice chronically infected with TMEV were treated with a total mAb dose of 0.5 mg iv or 5.0 mg ip divided into twice weekly doses for 4-5 weeks. CNS remyelination was measured by a quantitative morphological assessment on ten spinal cord cross-sections from each mouse. The criterion for CNS remyelination was abnormally thin myelin sheaths relative to axonal diameter. The data are composite of six experiments and are presented as the mean�SEM, where n indicates the number of mice. Statistical comparisons for remyelination data were made with the cumulative values from both IgM and buffer only controls using a modified rank sum test. The number of demyelinated lesions and the area of demyelination were not significantly different between treatment groups assessed by a one-way ANOVA. For control IgMs, we used myelomas MOPC 104E and ABPC 22 (both from Sigma), and TB5-1, an anti-mycobacteria mAb.
SJL/J mice chronically infected with TMEV and treated with either mAb SCH94.03 or SCH94.32 showed significantly greater CNS remyelination than animals treated with either isotype-matched control mAb or buffer only (Table 2).
TABLE 2__________________________________________________________________________Monoclonal antibodies SCH94.03 and SCH94.32 promote CNS remyelination Number Number of Area of Area Remyel Remyelination Area of Demyelination Lesion inatio n/AreaTreatment n Lesions Remyel (mm2) p-value Lesions (mm2) Lesion (%)__________________________________________________________________________SCH94.03 12 12.8 � 2.6 0.35 � 0.09 <0.0025 25.8 � 2.6 1.09 � 0.19 28.9 � 3.8SCH94.32 12 12.3 � 2.3 0.42 � 0.11 <0.0001 24.9 P � 2.8 1.46 � 0.21 26.7 � 4.2IgM control 13 6.7 � 1.2 0.11 � 0.02 -- 29.9 � 2.0 1.70 � 0.28 7.7 � 1.8Buffer only 11 5.1 � 1.1 0.06 � 0.01 -- 27.7 � 2.7 1.11 � 0.29 6.5 � 1.2__________________________________________________________________________
Remyelination was seen with either iv or ip injections. SCH94.03- or SCH94.32-treated animals had approximately 2-3-fold more remyelinated lesions, and a 3-4-fold larger total area of CNS remyelination than control animals. When a cumulative statistical comparison was made using these two parameters of therapeutic effectiveness, the CNS remyelination induced by mAbs SCH94.03 and SCH94.32 was highly significant (p<0,005; Table 2). In a chronic progressive disease like TMEV infection, the extent of CNS repair is a direct function of the extent of CNS damage. Both the number and area of CNS lesions were not different between treatment groups, indicating similar disease severity (Table 2). When CNS remyelination was expressed as the percentage of lesion area showing remyelination, approximately one-third of the cumulative demyelinated lesion area showed CNS remyelination in mice treated with either mAb SCH94.03 or SCH94.32 (Table 2).
CNS remyelination was readily identified morphologically both by light and electron microscopy (FIG. 3A-3D). FIG. 3A shows a remyelinated lesion from an animal treated with SCH94.03. The majority of axons in the lesion show morphologic evidence of repair, with abnormally thin myelin sheaths relative to axonal diameter (Ludwin, S. K. "Remyelination in the central nervous system of the mouse," In: THE PATHOLOGY OF THE MYELINATED AXON (Adachi M, Hirano A, Aronson SM eds), pp 49-79, Tokyo: Igaku-Shoin Ltd. (1985); Ludwin, S. K., Adv. Neurol., 47:215-254 (1988)). For comparison, FIG. 3B shows a demyelinated lesion, with minimal remyelination, whereas FIG. 3C is an area of normal myelin, with thickly myelinated axons. Within remyelinated lesions (FIG. 3A), there were 15.3�1.0 (mean�SEM) myelinated axons per 100 m2, compared to only 1.1�0.2 myelinated axons per 100 μm2 in demyelinated lesions (FIG. 3B). FIG. 3C shows a light micrograph of spinal cord section with normal myelin. By electron microscopy, CNS remyelination was especially evident (FIG. 3D). Almost every axon in the field has evidence of new myelin formation, although the degree of remyelination (i.e. myelin thickness) is variable between individual axons, suggesting different stages of the repair process. The ratio of myelin thickness to axonal diameter was 0.08�0.01 (mean�SEM; n=25 axons) for remyelinated axons compared to 0.21�0.01 (n=34 axons) for normally myelinated axons.
The correlation of morphological remyelination with clinical signs of disease improvement was assessed as described in Example 3. At each treatment injection, mice were assessed clinically as described in Example 3. The change in clinical score was correlated with the percentage of lesion area showing remyelination (FIG. 4). Morphological remyelination is represented as the percentage of lesion area showing CNS remyelination. A change in clinical score of 0 represent stable disease over the treatment period (4-5 weeks), whereas a positive change indicates worsening of clinical disease, and a negative change indicates improvement. Data represent individual animals from all treatment groups. A positive change in clinical score indicates worsening of disease. Using data from all treatment groups, the change in clinical score showed a moderate but significant negative correlation (R=-0.40; p<0.04) with the percentage of lesion area showing remyelination. Although few animals actually improved clinically (Δ clinical score<0), animals with an increase in disease severity (Δ clinical score>0) tended to have less morphological remyelination, while animals that remained stable clinically (Δ clinical score=0) showed the most remyelination. A similar negative correlation was obtained when the other quantitative measures of remyelination were used (the number of remyelinated lesions and the area of remyelination) as shown in Table 2. These data demonstrate that remyelination quantitated by morphology is associated with slowing of clinical disease progression.
For the initial treatment experiments, a total mAb dose of 25 mg/kg for iv injections and 250 mg/kg for ip injection was empirically chosen. To assess the dose-response characteristics, and to determine the minimal amount of mAb needed to promote remyelination, chronically-infected mice were treated with various ip doses of SCH94.03. Both the number of remyelinated lesions (data not shown) and the total area of remyelination (FIG. 5) increased significantly with larger doses of SCH94.03. Remyelination was quantitated as described for Table 2. Data are the mean values of 4-5 animals per mAb dose, with the final cumulative dose indicated on the graph. SEM averaged 35% of the mean. There was no statistical difference assessed by one-way ANOVA in the number of demyelinated lesions or the area of demyelination between treatment groups, indicating similar extent of disease in all animals. The number of demyelinated lesions and area of lesions were 33.2�7.5 and 1.25�0.43 for the 1000 μg group, 31.8�8 and 1.11�0.31 for the 100 μg group, 23.8�3.4 and 0.54�0.14 for the 10 μg group, and 29.0�6.5 and 0.74�0.20 for the buffer only group (represented as the 0 dose point on the graph). Animals treated with 100 μg control IgM (MOPC 104E) had remyelination scores similar to control animals treated with buffer only. The positive correlation between the dose of mAb SCH94.03 and CNS remyelination was especially striking when the severity of CNS disease was taken into account. When CNS repair was expressed as the percentage of lesion area showing remyelination, mice treated with a total dose of 1000, 100, or 10 μg of SCH94.03 had 6-, 5-, and 4-fold more remyelination than control animals, respectively (FIG. 5). Mice given as little as 10 μg of SCH94.03 ip (0.5 mg/kg) showed evidence of enhanced CNS remyelination. These data indicated that mAb SCH94.03 and CNS remyelination had a positive dose-response relationship, and that very small quantities of mAb were needed to promote myelin repair.
Although mAbs SCH94.03 and SCH94.32 were generated from splenocytes of uninfected mice, and screened against SCH from uninfected mice, it was directly assessed whether either mAb could react with TMEV capsid proteins or inhibit viral infectivity in vitro. By Western blotting (FIG. 6), SCH94.03 and SCH94.32 did not react with any TMEV proteins recognized by either serum from chronically infected mice or polyclonal IgG from rabbits injected with purified TMEV (Rodriguez, M., et al., Ann. Neurol., 13:426-433 (1983)). Western blot of lysates from control mock infected L2 cells showed single bands with the serum from chronically infected animals and the polyclonal rabbit anti-TMEV IgG at 32 and 43 kDa, respectively, but no reactivity with SCH94.03 or SCH94.32.
In addition, no significant inhibition of TMEV infectivity in vitro with up to 5 μg/ml of either SCH94.03 or SCH94.32, was observed under assay conditions where 50% neutralization was observed with a 1:34,000 dilution of serum from chronically infected animals. These results indicated that the therapeutic effect of SCH94.03 and SCH94.32 was not due to direct inhibition of the virus.
To initially characterize the antigens recognized by mAbs SCH94.03 and SCH94.32, various cell lines derived from glial (rat C6, mouse G26-20, human U373MG and U87MG), neural (human neuroblastoma), fibroblast (mouse L and 3T3), epithelial (human SCC-9 carcinoma), and lymphocytic (mouse CTLL2) origin were stained. Both mAbs stained internal antigens of all cell lines tested, which indicated that certain antigens recognized by these mAbs were not restricted to unique cell types in vitro. Based on the hypothesis that the therapeutic effect of SCH94.03 and SCH94.32 was due to a CNS-specific interaction, the immunostaining of cultured cells by SCH94.03 and SCH94.32 using the rat glial cell line 5.5B8 was further investigated. This immortalized glial cell line has phenotypic characteristics of both ac and astrocytes, with expression of MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), and low but detectable expression of glial fibrillary acidic protein (GFAP) and the lipids or proteins recognized by the mAbs A2B5 and 04 (Bozyczko, D. et al., Ann. NY Acad. Sci., 605:350-353 (1990)). SCH94.03 and SCH94.32 recognized both a surface and cytoplasmic determinant on 5.5B8 cells. The surface staining was most prominent on small cells which lay on top of a layer of flat, morphologically differentiated cells (FIG. 7A). Surface staining was confirmed by flow cytometry on live cells. When the cell membrane was permeabilized by dehydration or brief treatment with a non-ionic detergent to expose internal antigens, the staining pattern was altered considerably (FIG. 7B). The cytoplasmic staining was filamentous, with a dense perinuclear network that extended out into the cell processes. This pattern closely resembled the staining pattern of the intermediate filament cytoskeletal protein vimentin. These data indicated that SCH94.03 and SCH94.32 recognized antigens that were not restricted to cells derived from the nervous system, but that they did recognize both surface and cytoplasmic determinants on glial cells.
Immunohistochemical staining of frozen mouse, rat, and human tissue confirmed that SCH94.03 and SCH94.32 were not CNS-specific mAbs, but rather showed multi-organ reactivity. Both mAbs immunostained all major organs examined, including the brain, spinal cord, optic nerve, heart, liver, kidney, stomach, and small intestine and skeletal muscle. However, not all cells within an organ stained, suggesting in situ cytological specificity. Within the CNS, SCH94.03 and SCH94.32 stained predominantly blood vessels, ependymal cells, and stellate-shaped cells with the morphological features of glial cells, which were enriched in neonatal cerebellar, periventricular, and brain stem white matter (FIG. 7C), and both neonatal and adult optic nerve. Similar glial cells positive for SCH94.03 and SCH94.32 were found in autopsied human brain tissue, especially at the gray-white matter junction (FIG. 7D). Identical immunostaining results were obtained with mAb SCH94.32. Immunostaining with a control IgM (MOPC 104E) was negative for all samples and tissue structures which immunostained with SCH94.03 and SCH94.32.
The identification and characterization of an entire family of autoantibodies, referred to as "natural" or "physiological" autoantibodies, has influenced traditional views of autoimmunity and self-reactivity. The natural autoantibodies that have been studied extensively are typically IgMs, although other isotypes have been identified, are reactive toward a wide range of antigens, including cytoskeletal proteins, surface proteins, nucleic acids, phospholipids, bacterial antigens such as lipopolysaccharideS, and various chemical haptens (reviewed by Avrameas and Ternynck, Mol. Immunol., 30:1133-1142 (1993)). Natural autoantibodies share extensive idiotypic cross-reactivity or "connectivity", which includes expression of similar idiotypes, some of which are expressed by pathogenic autoantibodies, as well as reactivity toward common idiotypes expressed on other antibodies. Molecular analysis has shown that natural autoantibodies are typically encoded by unmutated germline immunoglobulin (Ig) genes, with few if any somatic mutations, and therefore represent a substantial fraction of the Ig repertoire, especially in neonatal animals which have not had extensive exogenous antigen exposure.
The function of natural autoantibodies remains enigmatic. Several hypotheses have been proposed based upon their biochemical and molecular characteristics. These include: (1) clearance of senescent or damage tissue, (2) providing a first line of immunological defense in the lag period between pathogen exposure and an Ag-specific immune response, (3) masking autoantigeus from a potentially pathogenic autoimmune response, (4) immunomodulation, including shaping of the neonatal immune repertoire via an idiotypic network, and (5) participation in the positive selection of B cells in the bone marrow, similar to the process proposed for T cells in the thymus.
The hypothesis that antibodies SCH94.03 and SCH94.32 were natural autoantibodies was tested. To characterize the antigen reactivities of SCH94.03 and SCH94.32, several biochemical and molecular assays, including immunohistochemistry and immunocytochemistry, Western blotting, solid-phase enzyme-linked immunosorbant assays (ELISA), and Ig variable region sequencing, were used. As described below, for all biochemical assays, SCH94.03 and SCH94.32 were indistinguishable. In addition, SCH94.03 and SCH94.32 had identical Ig variable region sequences, which confirmed that they were the same mAb.
A potential mechanism whereby SCH94.03 could stimulate remyelination in the central nervous system would be to stimulate the proliferation and/or differentiation of cells involved in myelinogenesis, primarily oligodendrocytes or their immature precursors. Thus, it was tested whether SCH94.03 stained the surface of various cells. Using immortalized cells, it was determined that SCH94.03 stained two glial cells lines, 5.5B8 (FIG. 7A) and 20.2E11, but did not stain the surface of several other glial cells lines (10.IA3, 20.2A40, C6, G26-20), a neuroblastoma cell line (B104), two fibroblast lines (L2, Cos-1), or two myoblastomas (G8, L6). Similar results were obtained with cells isolated from animal tissues and grown in culture. SCH94.03 stained the surface of oligodendrocytes, but not astrocytes, microglia, Schwann cells, myoblasts, or fibroblasts.
The reactivity of SCH94.03 with proteins from glial and lymphoid cell lines, and tissue lysates from brain, liver, and intestine by Western blotting was also assessed. SCH94.03 reacted with multiple bands from all cells and tissues examined, with prominent reactivity toward bands at 50, 95, 120, and >200 kDa. The exact identity of these protein bands has not been determined.
The reactivity of SCH94.03 with several purified protein self-antigens by solid-phase ELISA was determined. (FIG. 8A-8C). SCH94.03 showed strong reactivity toward the RBC antigen spectrin, but also showed consistent reactivity toward hemoglobin, actin, tubulin, and vimentin, and thyroglobulin, although to a lesser qualitative degree than toward spectrin. No reactivity was observed with myosin, transferrin, albumin, lysozyme, or myelin basic protein under our assay conditions. Six other monoclonal or myeloma IgM controls XXMEN-OE5 (FIG. 8B), A2B5, MOPC104E, TEPC183, 01, and CH12 (FIG. 8C), were also tested, and no reactivity with any of the antigens tested was observed.
To confirm the monoclonality of SCH94.03, 18 subclones of SCH94.03 (9 each from SCH94.03 and SCH94.32 parents) were tested for polyreactivity by solid-phase ELISA. All 18 subclones showed identical reactivity patterns with the panel of protein antigens as the parent SCH94.03. To further support the conclusion that the polyreactivity of SCH94.03 was via its Fab region, we generated F(ab)2 ' fragments and assessed their reactivity with the protein antigens by ELISA (FIG. 9). SCH94.03 F(ab)2 ' fragments showed similar polyreactivity as the whole IgM molecule.
A panel of chemical haptens coupled to bovine serum albumin (BSA) was constructed and used to assess SCH94.03 reactivity by solid-phase ELISA (FIG. 10A-10C). SCH94.03 showed strong reactivity toward fluorescein (FL) and 4-hydroxy-3-nitrophenyl acetic acid (NP), moderate reactivity toward phenyloxazolone (PhOx), and weak reactivity toward 2, 4, 6-trinitrophenyl (TNP) and p-azophenylarsonic acid (Ars). No reactivity with p-azophenyltrimethylammonium (TMA), p-azophenylphosphorylcholine (PC), or the carrier protein BSA was detected. Control IgMs (FIG. 10B and 10C) showed no significant binding to any of the haptens tested, with the exceptions of CH12 reactivity with TMA, which has been previously reported, and A2B5 reactivity with NP.
It was further investigated whether the Ig light (L) (SEQ ID NOS: 1 and 2 and heavy (H) (SEQ ID NOS: 6 and 7) chains of SCH94.03 were encoded by germline Ig genes (FIG. 11). The light chain variable (VL) and joining (JL) region nucleotide sequences from SCH94.03 (SEQ ID NOS: 1 and 2) had 99.4% identity with the previously published sequences of the germline VK10 (SEQ ID NO. 4) and JK1 (SEQ ID NO. 5) genes, with only two silent changes at the 3' end of both the VL and JL regions. The SCH94.03 VH (SEQ ID NOS: 6 and 7) region nucleotide sequence was identical to the previously published germline VH 23 (SEQ ID NO: 10) sequence, the JH region sequence differed from the published germline JH 2 (SEQ ID NO: 11) sequence by one nucleotide, at the 5' end of the J region, and the diversity (D) region contained 15 contiguous nucleotides derived from the germline DFL16.1 gene. There were 8 nucleotides in the V-D junction, and 1 in the D-J junction, which did not correspond to any known germline V or D region genes, and probably represent noncoded (N) nucleotides inserted by the enzyme terminal deoxynucleotide transferase during V-D-J recombination. The only changes from the germline genes in the heavy chain of SCH94.03 occurred at either the V-D or D-J junction, and therefore could represent either N nucleotides or the result of imprecise joining, rather than somatic mutations. In addition, both the light and heavy chain variable regions of SCH94.03 showed extensive sequence similarity with the IgM produced by the B-cell lymphoma CH12 (SEQ ID NOS: 3, 8 and 9) (FIG. 11).
These preliminary antigen reactivity results suggest that SCH94.03 is a natural autoantibody. Although this conclusion does not readily present a mechanism as to how SCH94.03 stimulates remyelination in the central nervous system, it does suggest an important physiological function of natural autoantibodies. Autoantibodies that are produced either during normal physiology, or in response to tissue damage and the subsequent release of previously sequestered antigens, might actively participate to promote repair in the damaged tissue. In line with previously proposed functions of natural autoantibodies, this active participation might be to facilitate removal of damaged tissue, mask autoantigens thereby preventing a vigorous pathogenic autoimmune response, modulate the immune response which actually resulted in the tissue destruction, thereby allowing normal endogenous tissue repair to occur, or directly stimulate cells involved in the repair process.
Thus, as a result of the work described herein, it is now demonstrated that an autoantibody generated and screened for its autoantigen-binding capability, also promotes CNS remyelination. Mice chronically infected with TMEV and treated either iv or ip with IgM mAbs from hybridomas SCH94.03 or SCH94.32 had significantly more CNS repair than control animals, measured by a detailed quantitative morphological assessment of CNS remyelination. Moreover, preliminary data suggest that the autoantibody, SCH94.03 is also effective in promoting remyelination in mammals afflicted with experimental autoimmune encephalomyelitis (EAE). Thus, it is reasonable to predict that autoantibodies, such as SCH94.03, play a critical role in stopping an immune-mediated process of demyelination in CNS diseases.
Two potential mechanisms can be proposed by which Abs promote remyelination. First, Abs might inhibit some pathogenic component of the disease process, such as virus activity, an immune response which directly induces demyelination, or an immune response which prevents remyelination. If the disease outcome is based upon a balance between tissue destruction and repair, inhibition of pathogenic components would allow a physiological repair response to predominate. Experimental and clinical evidence support this hypothesis. Spontaneous CNS remyelination is seen in MS patients and several experimental models of CNS demyelination as well as described herein, demonstrating spontaneous remyelination in control mice. This indicates that remyelination is a normal physiological response to myelin damage. In addition, treatment of mice chronically infected with TMEV with various immunosuppressive regiments promotes remyelination, but does not decrease demyelination, indicating that there is an immunological component which inhibits remyelination. (Rodriguez, M. and Lindsley, M. D., Neurology, 42:348-357 (1992)). Preliminary immunological function studies have indicated that animals treated with SCH94.03 had similar numbers of B and T (both CD4+ and CD8+) cells in their spleens compared to control animals, had similar in vitro splenocyte proliferative responses to mitogens and antigens, and mounted comparable Ab responses to both T cell-dependent and T cell-independent antigens.
The second hypothesis is that certain Abs can actively stimulate CNS remyelination, perhaps via stimulation of oligodendrocyte proliferation and/or differentiation in vivo, as has been demonstrated in vitro (Diaz, M. et al., Brain Res., 154:231-239 (1978); Raine, C. S., et al., Lab. Invest., 38:397-403 (1979); Lehrer, G. M. et al., Brain Res., 172:557-560 (1979); Bansal, R. et al., J. Neurosci. Res., 21:260-267 (1988); Benjamins, J. A. and Dyer, C. A., Ann. NY Acad. Sci., 605:90-100 (1990); Dyer, C. A., Mol. Neurobiol., 7:1-22 (1993)). MAb SCH94.03 may directly stimulate precursor glial cells which are known to be present at the edges of both human and experimental CNS lesions which show active remyelination. Alternatively, SCH94.03 may work indirectly, via activation of astrocytes or other accessory cells, which could release factors important for the survival or proliferation of cells in the oligodendroglial lineage. The formation of Ab-antigen complexes in situ with tissue components released upon myelin destruction may also participate in Ab-mediated CNS remyelination. Although SCH94.03 is not CNS-specific, the recognition of both surface and cytoplasmic antigens on glial cells by the mAb supports an active mechanism hypothesis. In contrast to the immunomodulatory hypothesis, which would not necessarily require that Abs have direct access to the CNS, the hypothesis that Abs actively stimulate CNS remyelination implies the prerequisite of direct access to the CNS. This is contrary to the view of the selective permeability of the blood-brain barrier, especially toward large molecules such as pentameric IgM. However, during chronic inflammatory conditions such as TMEV infection or MS, peripheral leukocytes migrate into the CNS, indicating an alteration in the blood-brain barrier permeability. Therefore, large proteins such as serum Ig might also enter, via either passive diffusion through "open" endothelium, or perhaps via an unidentified active transport mechanism.
The results of the experiments described herein have practical applications to multiple sclerosis (MS), EAE, and other related central nervous system demyelinating disorders. Rare examples of spontaneous CNS-type remyelination ("shadow plaques") are found in MS and occasional peripheral nervous system (PNS)-type remyelination is found in demyelinated spinal cord plaques near the root entry zone. Oligodendrocytes are infrequent at the center of the chronic plaques in MS but they appear to proliferate at the periphery of plaques, where they are associated with abortive remyelination. The process of remyelination may correlate with the spontaneous remission and improvements observed clinically in MS. These clinical observations indicate that new myelin formation is possible in MS. The remyelination that has been stimulated in mice with TMEV-induced demyelination by using a mAb may hold promise for therapeutic application in multiple sclerosis.
Of importance clinically is the question of whether morphologic regeneration of thin myelin sheaths contributes to functional recovery. Computer simulations indicate that new myelin formation even by inappropriately thin sheaths improves impulse conduction. Since the axon membrane of normally myelinated fibers is highly differentiated, it is necessary for sodium channels to be present at high density at the node of Ranvier to propagate saltatory conduction. Experimental evidence suggests that newly formed nodes do develop the required high sodium channel density as demonstrated by saxitoxin binding. Data to date suggest that remyelination even by inappropriately thin myelin improves conduction in a previously demyelinated axon. Therefore, any strategy to promote this morphologic phenomenon has the potential of producing functional recovery.
The data presented herein demonstrates, for the first time, that administration of a monoclonal antibody to a mammal is capable of stimulating remyelination of central nervous system axons in vivo. Specifically, treatment of chronically infected TMEV-infected mice with as little as 10 ug of SCH94.03 resulted in a 4- to 5-fold increase in the total area of CNS myelination compared to mice treated with a control mAb.
Thus, as a result of the experiments described herein, the method of the present invention can be used to treat mammals, including humans and domestic animals, afflicted with demyelinating disorders, and to stimulate remyelination of the CNS axons. As described herein, an effective amount of the monoclonal antibody can be administered by intravenous (iv) or intraperitoneal (ip) injection. An effective amount of the antibody can vary depending on the size of the mammal being treated, the severity of the disease, the route of administration, and the course of treatment. For example, each dose of mAb administered can range from approximately 0.5 mg/kg to approximately 400 mg/kg, with the preferred range from approximately 0.5 mg/kg to approximately 250 mg/kg. It is important to note that a dose as low as 10 μg (0.5 mg/kg) was effective in promoting remyelination of CNS axons in mice. The dose of mAb will also depend on the route of administration. For example, an iv dose administered to mice was 0.5 mg/kg, and an ip dose was 5.0 mg/kg. The course of treatment includes the frequency of administration of the mAb (e.g, daily, weekly, or bi-weekly) and the duration of the treatment (e.g, four weeks to four months). Thus, for example, a larger amount of mAb can be given daily for four to five weeks, as opposed to a smaller amount of mAb given for four months.
The effectiveness of the amount of the monoclonal antibody being administered can be assessed using any number of clinical criteria, for example, as described in Example 3, including overall appearance of the mammal, the activity of the mammal and the extent of paralysis of the mammal. The effectiveness of the amount of monoclonal antibody necessary to induce remyelination in humans can also be assessed in a double blinded controlled trial. Patients with fixed neurological deficits from demyelinating disease can be treated with monoclonal antibody or controls. Improvement in isometric muscle strength as detected by quantitative biomechanics muscle testing could be used as the primary therapeutic end-point.
An effective amount of the monoclonal antibody can be combined with, or diluted with, an appropriate pharmaceutically acceptable carrier, such as a physiological buffer, or saline solution. Additionally, the monoclonal antibody may be genetically altered, e.g. "humanized" by the substitution of human antibody nucleotide sequences in nonvariable regions of the murine mAb to reduce immunogenicity.
In addition to in vivo methods of promoting remyelination, ex vivo methods of stimulating remyelination in CNS axons are also encompassed by the present invention. For example, the monoclonal antibody may be used in vitro to stimulate the proliferation and/or differentiation of glial cells, such as oligodendrocytes, as described in Example 2. These exogenous glial cells can then be introduced into the CNS of mammals using known techniques. Remyelination of CNS axons would be increased by increasing the number of endogenous glial cells present (glial cells, such as oligodendrocytes play a critical role in the production of myelin).
In vitro methods of producing glial cells, or stimulating the proliferation of glial cells from mixed culture (e.g., rat optic nerve cell, or rat brain cell cultures) are also encompassed by this invention. For example, cells obtained from rat optic nerve, or rat brain, containing glial cells, are cultured as a mixed culture under conditions sufficient to promote growth of the cells. An effective amount of mAb capable of promoting remyelination of CNS axons, such as SCH94.03, is then added to the mixed culture of cells and maintained under conditions sufficient for growth and proliferation of cells. The mAb stimulates the proliferation of glial cells in the mixed culture. Thus the proliferation of glial cells cultured in the presence of the mAb is increased, relative to the proliferation of glial cells grown in the absence of the mAb.
The invention will be further and more specifically illustrated by the following Examples, which are not intended to be limiting in any way.
Spleens of two SJL/J mice (Jackson Laboratories, Bar Harbor, Me.) that had been injected twice with spinal cord homogenate (SCH) in incomplete Freund's adjuvant were used as the source of B cells for fusion and hybridoma production. Splenocytes were fused with NS-1 myeloma cells using polyethylene glycol, and viable cell fusions were selected with hypoxanthine-aminopterin-thymidine (HAT) media and cloned by limiting dilution as described (Katzmann, J. A. et al., Proc. Nat. Acad. Sci. USA, 78:162-166 (1981)).
Hybridoma supernatants from viable Ig-producing clones were screened for binding to SCH by an enzyme-linked immunosorbant assay (ELISA). The following antigens were used for screening mAbs: SCH--(10 μg) reconstituted in carbonate-bicarbonate buffer (pH 8.53), MBP--(1 μg) dissolved in PBS, GC (1 μg) dissolved in absolute alcohol, PLP (1 μg) dissolved in water. PLP was provided by Dr. W. Macklin (UCLA) who has published a solid phase immunoassay for PLP. For SCH, MBP or GC ELISA, Immuno II plates were coated with prepared antigen (100 μl/well) which was incubated overnight at 4� C. The following day wells were washed in PBS and blocked with PBS+1% serum for 1 hr at room temperature. Plates were washed again in PBS and serial dilutions of primary Ab diluted in PBS/0.1% BSA were added and incubated at room temperature for 2 hrs. Plates were washed in PBS/0.05% Tween and appropriate secondary Ab conjugated to alkaline phosphatase (1:1000 in PBS 0.1% BSA) was added. Plates were incubated at 37� C. for 2 hrs, washed in PBS 0.05% Tween, and the substrate (Sigma 104 Phosphatase Substrate Tablet in 5 ml diethanolamine buffer) was added for 30 min. The reaction was terminated with 50 μl of 1N NaOH. The plates were read on a Dynatech ELISA plate reader.
The hybridomas chosen for treatment experiments were injected into pristane-treated BALB/c mice for ascites production. Hylridomas were also grown in RPM1-1640 media supplemented with 10% fetal bovine serum for IgM production. IgM mAbs were purified by either ammonium sulfate precipitation and gel filtration on a Sephacryl S-400 HR (Sigma) column for the initial transfer experiments, or by affinity chromatography using goat anti-mouse IgM (μ-chain specific; Jackson Immunoresearch, West Grove, Pa.) coupled to Reacti-Gel 6� matrix (Pierce, Rockford, Ill.) for later transfer experiments.
The ability of the mAbs to promote proliferation of glial cells in vitro was tested. Glial cells isolated from rat brain or optic nerves were seeded in Falcon Microtest II plates at a concentration of 2�104 cells per well in 0.1 ml of DME. Whole serum (SCH, IFA, MBP, GC, MBP/GC, PBS or PLP), purified Ig or mAb, was serially diluted and 0.1 ml aliquot was added to cells and assayed in triplicate. Three days later 3 H-thymidine was added (1 μCi/ml) and cells were harvested after 17 hrs with an automated cell harvester (Mash II Harvester). To document identity of cells proliferating (i.e., , astrocytes, progenitor glial cells, macrophages), selected cultures after exposure to 3 H-thymidine, were incubated with appropriate Ab specific for cell type followed by ABC immunoperoxidase technique. After reaction of Hanker-Yates reagent, the slides were immersed in Ilford K2 nuclear emulsions, exposed for 4 days at 4� C. and developed.
One- to two-day-old rats were killed with ether. Through careful dissection, optic nerves were removed from the optic nerve chiasm to the eye. Nerves were transferred to centrifuge tubes containing 2 mls of DMEM. An equal volume of 0.25% trypsin was added and incubated to 37� C. in a water bath for 45 min. 0.2 ml of FCS was added to terminate trypsinization. Nerves were passed through a sterile needle and syringe (gauge no. 21) and then centrifuged at 1400 rpm for 10 min. The cell count was adjusted to provide concentration of 5�105 cells/100 μl of media in 24-well trays in DMEM+0.5% FCS. After 12 to 16 hrs, appropriate antibodies or growth media were added as per experimental protocols.
Brains of 1-2 day old rats were removed and placed in Hank's Balanced Salt Solution with 10 mM HEPES buffer (HBSS/H), approximately 1-2 ml per brain. The brain stem, cerebellum, and midbrain was discarded whereas the forebrain was minced with a bent syringe. The tissue was further disrupted by repeated passage through a 10 ml pipet and transferred to a 50 ml conical tube. The tissue suspension was shaken on a rotary shaker (75 rpm) for 30 min at 37� C. Trypsin was added to a final concentration of 0.125% and the suspension was shaken for an additional 60 min. Trypsin digestion was stopped by adding FCS (10%). The cell suspension was passed sequentially through 120 and 54 μm Nytex, centrifuged, resuspended in serum-free medium with 10% FCS, and filtered again through 54 μm Nytex. Serum-free media was DMEM with 3.7 g/l sodium bicarbonate, 6.0 g/l glucose, 2 mM L-glutamine, 0.1 nM nonessential amino acids, 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml selenite, 100 U/ml penicillin and 100 μg/ml streptomycin. The cells were counted, plated onto uncoated tissue culture flasks or plates at 5�104 cells/cm2 and cultured at 37� C. in 5% CO2. The media was changed after 72 hrs, and every 48 hrs thereafter. On day 8 after culture initiation, the media was aspirated and replaced by SFM with various supplements (for example, antibody). For most experiments, the cells were grown for an additional 48 hrs before harvesting. Cells were pulsed with [3 H]thymidine (5 μCi/ml) for the final 1824 hrs of culture.
Antigens were denatured and solubilized by heating at 100� C. in sodium dodecyl sulfate (SDS) sample buffer. Samples were electrophoresed on stacking and separating gels containing 4.75% and 12.0% acrylamide at 200 volts. After electrophoresis, gels and nitrocellulose membranes were equilibrated for 30 min in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.1-8.3). All steps were done at room temperature. Gels were electroblotted for either 1 hr at 100 V or overnight at 30 V using the Bio-Rad Mini Trans-blot apparatus. The nitrocellulose membrane was cut into strips and washed, 3� TBS (100 mM NaCI, 50 mM TriG, pH 7.6) with 0.03% Tween 20. Nitrocellulose strips were blocked (TBS with 3% non-fat milk and 0.03% Tween 20) for 2-4 hrs, washed 3�, and incubated with primary Ab or antisera (diluted in blocking buffer) for 4 hrs or overnight. After primary Ab incubation, strips were washed 3�, incubated with either biotin- or alkaline phosphate-labelled secondary Ab (diluted in blocking buffer) for 2 hrs, washed 3�, and incubated with alkaline-phosphatase labeled-streptavidin (diluted in blocking buffer) for 2 hrs if the biotin system is used. Nitrocellulose strips were washed 4� (final wash in TBS without Tween 20) and incubated with substrate solution (0.165 mg/ml BCIP and 0.33 mg/ml NBT in 100 mM NaCI, 100 mM TriG, 5 mM MgG12, pH 9.5) until sufficient color developed (approximately 10-15 min). The reaction was stopped by adding PBS with 5 mM EDTA.
Cell lines or mixed brain cultures were lysed in 1� SDS reducing sample buffer (2.3% SDS, 10% 2-ME, 0.125M Tris, 20% glycerol) and heated to 85� C. for 15 min. Nucleic acids were sheared by repeated passage of lysate through 21-27-gauge needles. Lysate proteins were separated on a 12% acrylamide reducing gel, transferred to nitrocellulose membranes, and blotted with various antibodies as previously described.
The DA strain of TMEV was obtained from Drs. J. Lehrich and B. Arnason after eight passages in BHK cells. The virus was passaged an additional four times at a multiplicity of infection of 0.1 plaque forming units (PFU) per cell. Cell-associated virus was released by freeze-thawing the cultures followed by sonication. The lysate was clarified by centrifugation and stored in aliquots at -70� C. All subsequent experiments will use passage 12 virus. This virus isolate causes white matter pathology without destruction of anterior horn cells.
Viral plaque assays were done as previously described (Patick, A. K., et al., J. Neuropath. Exp. Neurol., 50:523-537 (1991)). To assess neutralization, aliquots of TMEV (200 PFU/ml) were incubated with various concentrations of Ab for 1 hour at room temperature prior to plating onto confluent L2 cells. As a positive control, we used serum from susceptible mice chronically infected with TMEV. Under the assay conditions described above, a serum dilution of 1:34,000 gave 50% neutralization, which corresponded to an estimated 20 ng/ml of TMEV-specific Abs, assuming a total serum Ig concentration of 15 mg/ml, and a TMEV-specific fraction of 5%.
Demyelination was induced in female SJL/J mice, ages four to six weeks, from the Jackson Laboratory, Bar Harbor, Me. Mice were inoculated intracerebrally with 2�105 plaque-forming units of DA virus in a volume of 10 μl. Mice infected chronically with TMEV (4 to 6 months following infection) were assigned randomly to groups of treatment.
Chronically infected mice were given either intraperitoneal (ip) or intravenous (iv) injections of mAb twice weekly for 4-5 weeks. At each treatment injection, mice were assessed clinically by three criteria: appearance, activity, and paralysis. A score for each criterion was given ranging from 0 (no disease) to 3 (severe disease). For appearance, 1 indicated minimal change in coat, 2 indicated a moderate change (scruffy appearance), and 3 indicated a severe change (incontinence and stained coat). For activity, 1 indicated decreased spontaneous movements (minimal ataxia), 2 indicated moderate slowing (minimal spontaneous movements), and 3 indicated severe slowing (no spontaneous movement). For paralysis, 0.5 indicated a spastic extremity, 1 indicated a paralyzed extremity, 1.5 indicated two or more spastic extremities, 2 indicated two paralyzed extremities (unable to walk), 2.5 indicated no righting response, and 3 indicated three or four paralyzed extremities (moribund). The total score for each mouse was the cumulative total from each criterion (maximum of 9). As the clinical score was an ordinal, but not a cardinal scale, the change in clinical score to assess clinical disease was used. The clinical assessment data were not disclosed until after the morphological assessment of remyelination was completed.
Preparation of light and electron microscopy sections and morphological assessment of remyelination were done. Briefly, treated mice were anesthetized with pentobarbital (0.2 mg ip), exsanguinated by cardiac puncture, and killed by intracardiac perfusion with Trump's fixative (100 mM phosphate buffer, pH 7.2, with 4% formaldehyde and 1.5% glutaraldehyde). The entire spinal cord was removed carefully from the spinal canal, and sectioned into 1 mm transverse blocks. Every third block was post-fixed in 1% osmium tetroxide and embedded in Araldite (Polysciences, Warrington, Pa.). One micron sections from each block were cut and stained with p-phenylenediamine. On each section, remyelination was quantitated using a Zeiss interactive digital analysis system (ZIDAS) and camera lucida attached to a Zeiss photomicroscope (Carl Zeiss Inc., Thornwood, N.Y.). Abnormally thin myelin sheaths relative to axonal diameter was used as the criterion for CNS remyelination. Ten spinal cord sections from each mouse were examined; this corresponded to 8-9 mm2 of white matter examined per mouse. To avoid bias, slides were coded and quantitation was done without knowledge of the treatment groups.
Electron micrographs of normal and remyelinated axons from plastic-embedded spinal cord sections were imaged with a Hamamatsu video camera, digitized, and analyzed using an IBAS 2000 Image Analysis System (Kontron, Munich, Germany). The axonal cross-sectional area with and without the myelin sheath was measured, and equivalent circle calculations were used to determine the axonal diameter and myelin sheath thickness. For myelinated axon quantitation, the number of myelinated axons in lesions from plastic-embedded spinal cord sections were counted using the analysis system described above attached to an Axiophot microscope (Carl Zeiss, Inc.). 17 remyelinated and 15 demyelinated lesions in spinal cord sections from animals treated with mAb SCH94.03, control IgM, or buffer only were analyzed. This corresponded to 0.6 mm2 of remyelinated area and 0.8 mm2 of demyelinated area. The criterion for selection of a lesion as demyelinated was the presence of substantial demyelination with minimal repair, whereas remyelinated lesions were chosen based upon the presence of almost complete remyelination throughout the lesion.
Rat 5.5B8 glial cells were grown on poly-D/L-lysine-coated chamber slides in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1.5 g/L D-glucose, 30 nM SeO2, 15 nM triiodothyronine, 10 ng/ml biotin, 100 μM ZnCl2, 50 μg/ml gentamicin, and 10% fetal bovine serum. All staining steps were done at room temperature. For surface staining, slides were briefly rinsed with PBS, and cells were lightly fixed with 1% formaldehyde in PBS for 10 min to prevent cell detachment during subsequent staining steps. For cytoplasmic staining, slides were rinsed twice in PBS and either air dried for 1 hour or incubated with 0.1% Triton X-100 in PBS for 10 min. Cells were blocked in 2% BSA for 30 min, washed, incubated with control IgM or mAb SCH94.03 (10 μg/ml in 1% BSA) for 1 hour, and washed extensively with PBS. After fixation with 4% paraformaldehyde for 15 min, slides were incubated with fluorescein-labeled goat anti-mouse IgM (Jackson Immunoresearch) for 1 hour, washed with PBS, coverslipped with 10% MOWIOL� (Hoechst) in 100 mM Tris, 25% glycerol, pH 8.5 with 25 μg/ml 1,4-diazobicyclo-[2.2.2]-octane (DABCO) to prevent fading, and allowed to set overnight in the dark. For frozen tissue sections, fresh neonatal rat, adult mouse, or autopsied human cortical brain tissue was quick frozen in isopentane chilled in liquid nitrogen prior to liquid nitrogen storage. Frozen sections (10 μm) were transferred onto gelatinized glass microscope slides, air dried for 4-8 hours, and stored at -70� C. Prior to immunostaining, slides were placed at room temperature overnight. The immunoperoxidase staining protocol was similar that described above, using the ABC immunoperoxidase reagent (Vector Laboratories, Burlingame, Calif.), developed with 1.5 mg/ml Hanker-Yates reagent (p-phenylene diamine-procatechol) in 50 mM Tris, pH 7.6 with 0.034% H202, counterstained with Mayer's hematoxylin, and mounted with Permount (Fischer Scientific, Pittsburgh, Pa.).
A modified cumulative rank sum test (O'Brien, P. C., Biometrics, 40:1079-1087 (1984)) was used to compare remyelination between treatment groups. This statistical test takes into account several numerically unrelated parameters of therapeutic effectiveness, and is used routinely for clinical trial efficacy assessment. Parallel analyses using a standard unpaired Student's t-test to compare individual parameters of remyelination gave equivalent results. Comparisons of disease severity and correlation significance were determined by a one-way analysis of variance (ANOVA). Statistical analyses were done with the either the SigmaStat (Jandel Scientific, San Rafael, Calif.) or EXCEL (Microsoft Corporation, Redmond, Wash.) software programs. Calculated values were considered significant when p was <0.05.
Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims:
__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 11(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 393 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 1..393(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:ATGATGTCCTCTGCTCAGTTCCTTGGTCTCCTGTTGCTCTGTTTTCAA48MetMetSerSerAlaGlnPheLeuGlyLeuLeuLeuLeuCysPheGln151015GGTACCAGATGTGATATCCAGATGACACAGACTACATCCTCCCTGTCT96GlyThrArgCysAspIleGlnMetThrGlnThrThrSerSerLeuSer202530GCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGGGCAAGTCAGGAC144AlaSerLeuGlyAspArgValThrIleSerCysArgAlaSerGlnAsp354045ATTAGCAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTT192IleSerAsnTyrLeuAsnTrpTyrGlnGlnLysProAspGlyThrVal505560AAACTCCTGATCTACTACACATCAAGATTACACTCAGGAGTCCCATCA240LysLeuLeuIleTyrTyrThrSerArgLeuHisSerGlyValProSer65707580AGGTTCAGTGGCAGTGGGTCTGGAACAGATTATTCTCTCACCATTAGC288ArgPheSerGlySerGlySerGlyThrAspTyrSerLeuThrIleSer859095AACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAAT336AsnLeuGluGlnGluAspIleAlaThrTyrPheCysGlnGlnGlyAsn100105110ACGCTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAACGG384ThrLeuProTrpThrPheGlyGlyGlyThrLysLeuGluIleLysArg115120125GCTGATGCT393AlaAspAla130(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 131 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:MetMetSerSerAlaGlnPheLeuGlyLeuLeuLeuLeuCysPheGln151015GlyThrArgCysAspIleGlnMetThrGlnThrThrSerSerLeuSer202530AlaSerLeuGlyAspArgValThrIleSerCysArgAlaSerGlnAsp354045IleSerAsnTyrLeuAsnTrpTyrGlnGlnLysProAspGlyThrVal505560LysLeuLeuIleTyrTyrThrSerArgLeuHisSerGlyValProSer65707580ArgPheSerGlySerGlySerGlyThrAspTyrSerLeuThrIleSer859095AsnLeuGluGlnGluAspIleAlaThrTyrPheCysGlnGlnGlyAsn100105110ThrLeuProTrpThrPheGlyGlyGlyThrLysLeuGluIleLysArg115120125AlaAspAla130(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 324 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACC60ATCAGTTGCAGGGCAAGTCAGGACATTAGCAATTATTTAAACTGGTATCAGCAGAAACCA120GATGGAACTGTTAAACTCCTGATCTACTACACATCAAGATTACACTCAGGAGTCCCATCA180AGGTTCAGTGGCAGTGGGTCTGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAA240GAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCCTCCGACGTTCGGTGGA300GGCACCAAGCTGGAAATCAAACGG324(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 285 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACC60ATCAGTTGCAGGGCAAGTCAGGACATTAGCAATTATTTAAACTGGTATCAGCAGAAACCA120GATGGAACTGTTAAACTCCTGATCTACTACACATCAAGATTACACTCAGGAGTCCCATCA180AGGTTCAGTGGCAGTGGGTCTGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAA240GAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCCT285(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:TGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAACGT39(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 429 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 1..429(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:ATGGGATGGAGCTGTATCATCCTCTTTTTGGTAGCAGCAGCTACAGGT48MetGlyTrpSerCysIleIleLeuPheLeuValAlaAlaAlaThrGly151015GTCCACTCCCAGGTCCAACTGCAGCAGCCTGGGACTGAACTGGTGAAG96ValHisSerGlnValGlnLeuGlnGlnProGlyThrGluLeuValLys202530CCTGGGGCTTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACCTTC144ProGlyAlaSerValLysLeuSerCysLysAlaSerGlyTyrThrPhe354045ACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGACAAGGCCTT192ThrSerTyrTrpMetHisTrpValLysGlnArgProGlyGlnGlyLeu505560GAGTGGATTGGAAATATTAATCCTAGCAATGGTGGTACTAACTACAAT240GluTrpIleGlyAsnIleAsnProSerAsnGlyGlyThrAsnTyrAsn65707580GAGAAGTTCAAGAGCAAGGCCACACTGACTGTAGACAAATCCTCCAGC288GluLysPheLysSerLysAlaThrLeuThrValAspLysSerSerSer859095ACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTC336ThrAlaTyrMetGlnLeuSerSerLeuThrSerGluAspSerAlaVal100105110TATTATTATGCAAGACGGGCCCCTTACTACGGTAGTAGGAACTTTGAC384TyrTyrTyrAlaArgArgAlaProTyrTyrGlySerArgAsnPheAsp115120125TACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAGAGAGTCAG429TyrTrpGlyGlnGlyThrThrLeuThrValSerSerGluSerGln130135140(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 143 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:MetGlyTrpSerCysIleIleLeuPheLeuValAlaAlaAlaThrGly151015ValHisSerGlnValGlnLeuGlnGlnProGlyThrGluLeuValLys202530ProGlyAlaSerValLysLeuSerCysLysAlaSerGlyTyrThrPhe354045ThrSerTyrTrpMetHisTrpValLysGlnArgProGlyGlnGlyLeu505560GluTrpIleGlyAsnIleAsnProSerAsnGlyGlyThrAsnTyrAsn65707580GluLysPheLysSerLysAlaThrLeuThrValAspLysSerSerSer859095ThrAlaTyrMetGlnLeuSerSerLeuThrSerGluAspSerAlaVal100105110TyrTyrTyrAlaArgArgAlaProTyrTyrGlySerArgAsnPheAsp115120125TyrTrpGlyGlnGlyThrThrLeuThrValSerSerGluSerGln130135140(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 366 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 1..366(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:CAGGTCCAACTGCAGCAGCCTGGGACTGAACTGGTGAAGCCTGGGGCT48GlnValGlnLeuGlnGlnProGlyThrGluLeuValLysProGlyAla151015TCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACCTTCACCAGCTAC96SerValLysLeuSerCysLysAlaSerGlyTyrThrPheThrSerTyr202530TGGATGCACTGGGTGAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATT144TrpMetHisTrpValLysGlnArgProGlyGlnGlyLeuGluTrpIle354045GGAAATATTAATCCTAGCAATGGTGGTACTAACTACAATGAGAAGTTC192GlyAsnIleAsnProSerAsnGlyGlyThrAsnTyrAsnGluLysPhe505560AAGAGCAAGGCCACACTGACTGTAGACAAATCCTCCAGCACAGCCTAC240LysSerLysAlaThrLeuThrValAspLysSerSerSerThrAlaTyr65707580ATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTATTAT288MetGlnLeuSerSerLeuThrSerGluAspSerAlaValTyrTyrTyr859095GCAAGAGATTACTACGGTAGTAGCTGGGGGTACTACTTTGACTACTGG336AlaArgAspTyrTyrGlySerSerTrpGlyTyrTyrPheAspTyrTrp100105110GGCCAAGGCACCACTCTCACAGTCTCCTCA366GlyGlnGlyThrThrLeuThrValSerSer115120(2) INFORMATION FOR SEQ ID NO:9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 122 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:GlnValGlnLeuGlnGlnProGlyThrGluLeuValLysProGlyAla151015SerValLysLeuSerCysLysAlaSerGlyTyrThrPheThrSerTyr202530TrpMetHisTrpValLysGlnArgProGlyGlnGlyLeuGluTrpIle354045GlyAsnIleAsnProSerAsnGlyGlyThrAsnTyrAsnGluLysPhe505560LysSerLysAlaThrLeuThrValAspLysSerSerSerThrAlaTyr65707580MetGlnLeuSerSerLeuThrSerGluAspSerAlaValTyrTyrTyr859095AlaArgAspTyrTyrGlySerSerTrpGlyTyrTyrPheAspTyrTrp100105110GlyGlnGlyThrThrLeuThrValSerSer115120(2) INFORMATION FOR SEQ ID NO:10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 351 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:ATGGGATGGAGCTGTATCATCCTCTTTTTGGTAGCAGCAGCTACAGGTGTCCACTCCCAG60GTCCAACTGCAGCAGCCTGGGACTGAACTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCC120TGCAAGGCTTCTGGCTACACCTTCACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCT180GGACAAGGCCTTGAGTGGATTGGAAATATTAATCCTAGCAATGGTGGTACTAACTACAAT240GAGAAGTTCAAGAGCAAGGCCACACTGACTGTAGACAAATCCTCCAGCACAGCCTACATG300CAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTATTATGCAAGA351(2) INFORMATION FOR SEQ ID NO:11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 45 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:TACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA45__________________________________________________________________________
Patent Citations
Non-Patent Citations
Referenced by
Legal Events
Original Image


text:
to choke yourself while masturbating and not letting go until you have climaxed
i was felling depressed and horny at the same time last night, so i had a blue pope.
by haha fucker! July 31, 2005
10 Words Trending Now
Alphabetical List
Type your email address below to get our free Urban Word of the Day every morning!
Emails are sent from email@example.com. We'll never spam you.×


text:
This Business is not BBB Accredited
EA Electric
Phone: (214) 349-0201Fax: (214) 348-03902941 Trade Canter Dr, Ste 200, Carrollton, TX 75007 ! There is an alert for this business !
BBB Business Reviews may not be reproduced for sales or promotional purposes.
BBB Accreditation
EA Electric is not BBB Accredited.
Businesses are under no obligation to seek BBB accreditation, and some businesses are not accredited because they have not sought BBB accreditation.
To be accredited by BBB, a business must apply for accreditation and BBB must determine that the business meets BBB accreditation standards, which include a commitment to make a good faith effort to resolve any consumer complaints. BBB Accredited Businesses must pay a fee for accreditation review/monitoring and for support of BBB services to the public.
Reason for Rating
BBB rating is based on 16 factors. Get the details about the factors considered.
This business has no rating because BBB has information indicating it is out of business.
Customer Complaints Summary
|Complaint Type
|Total Closed Complaints
|Advertising / Sales Issues
|Billing / Collection Issues
|Problems with Product / Service
|Delivery Issues
|Guarantee / Warranty Issues
|Total Closed Complaints
Additional Informationtop
Licensing, Bonding or Registration
This company is in an industry that may require licensing, bonding or registration in order to lawfully do business. BBB encourages you to check with the appropriate agency to be certain any requirements are currently being met.
These agencies may include:Texas Department of Licensing & Regulation
PO Box 12157, Capitol Station
Austin, TX78711
(800) 803-9202
Type of Entity
Limited Liability Corporation
Contact InformationPrincipal: Mr. Andy Moreno (President)
Business Category
Electricians, Electricians - Commercial


text:
Welcome to the Official Site for BSA Troop 1, Madison, CT!
We are Madison's first Boy Scout troop, started over 100 years ago!!
Like Adventure?
Rock Climbing Adventures
Thrilling Whitewater Canoe Trips
Skiing the Big Mountains of New England
Wilderness Survival Weekends
Learning Critical Survival & Leadership
skills beneficial for life…and much more!
All with your BEST FRIENDS!!
Troop 491 Madison
Everyone Welcome (All ages)
No Experience necessary!
Want to learn more?
Please drop by our Open House:
Monday November 3, 2014 7:30 pm – 9:00 pm
American Legion Hall 43 Bradley Road, Madison
For more information contact:
Rich Morrison (203) 843-0845


text:
16 Oct
Here are 8 players who have something Kentucky wishes it had
With little surprise, Kentucky was voted No. 1 in the USA TODAY Sports Coaches Poll and has towering expectations for the 2014-15 (…)
10 Oct
John Calipari is expecting 90 NBA representatives at practice today
According to the Kentucky coach, a whopping 90 NBA personnel members are going to attend Friday's NBA Pro Day, which will be (…)
18 Sep
John Calipari gives away beds, pillows to Kentucky fans camping out for Big Blue Madness
Five students got Tempur-Pedic mattresses because, apparently, their sleeping setup at Tent City really needed an upgrade.
21 Aug
John Calipari and Mike Francesa going at it makes for sports-talk magic
The two argued about Francesa's opinion of Calipari as a coach.
30 Jul
The one thing that 1/5 of the players at USA Basketball training camp have in common
John Calipari tweeted out a reminder that he has coached a whopping 21% of the players at USA Basketball training camp right now.
22 Jul
John Calipari: 'Boy is it nice to have returning players'
What happens when potential one-and-done players stay in school.


text:
It is highly optimized for performance and usability without a needlessly complex user interface.
- Detect moved and renamed files and folders
- Copy locked files (Volume Shadow Copy Service)
- Detect conflicts and propagate deletions
- Binary comparison
- Full support for Symbolic Links
- Automate sync as a batch job
- Multiple folder pairs
- Copy NTFS extended attributes (compressed, encrypted, sparse)
- Copy NTFS security permissions
- Support long path names > 260 characters
- Fail-safe file copy
- Cross-platform: Windows/Linux
- Expand environment variables like %USERPROFILE%
- Access variable drive letters by volume name (USB sticks)
- Native 32 and 64-bit builds
- Keep versions of deleted/updated files
- Optimal sync sequence prevents disc space bottlenecks
- Full unicode support
- Highly optimized performance
- Include/exclude files via filter
- Local and portable installation
- Handle daylight saving time changes on FAT/FAT32
- Use macros %time%, %date%, et al. for recurring backups
- Case sensitive synchronization
- Built-in locking serializes multiple jobs running against the same network share
What's New:
- Fixed crash when accessing recycle bin in compatibility mode (Windows 7, 8)
- Draw middle grid selection irrespective of focus column
- Don't show parts of progress graph if nothing to sync
- Break on missing directories before evaluating warnings
- Ignore leading/trailing whitespace in search panel
- Disable search panel during comparison
- Disable shortkeys during comparison
- Log folder pair only if files are synced
- Fixed number separator formatting for english locale
- Copying locked files now inactive by default
- Show all affected folders when warning about a shared sub folder
Software that can be used as an alternative to FreeFileSync:


text:
Location: Manatee Oaks Subdivision, Bradenton
Do Not Show Listings
$200,000169 Days on yellowkey MLS ID: A4100136
INCREASED by $10,100 (5.3%) on 10/09/2014
Bed: 3 Bath: 2.5 Gar: 2 Liv Area Sq Ft: 1501 Built: 1986Monthly Fee: $22 Tax: $1,186 (2013)Community: Manatee Oaks SubdivisionPool: NoSingle Family, Pets Allowed
Market Analysis:
For SaleFor RentSoldRented
Nearby Properties:
For SaleFor RentSoldRented
SaveRemove Favorite |
Email |
Directions |
Virtual Tour
Crime Info
Elementary School: None
High School: None
Tax Year: 2013
Middle School: None
Remarks: Manatee Oaks is a mature landscaped neighborhood that you can make your home with this beautiful custom waterfront property. A two story gem like this is not likely in today's market! Near 301, SR-70, I-75, beaches, airport and downtown Sarasota/Bradenton. Enjoy your morning coffee in the private oasis of a backyard while watching the wildlife thrive on the waterfront or host a grand bar-b-que in your oversized lanai! Your guests will be comfortable on the second floor complete with two bedrooms and full bath while you can rest in your private bedroom with en suite. The great room features a terrific fireplace ready for those cool February evenings. Hurricane windows, newer paint, newer A/C and rain barrels are just a few of the extras you can enjoy. The home features an open floor plan with endless possibilities for setting up your new abode. Come visit today and never leave!
Listing is courtesy of: PREMIER PLUS REALTY (941-955-1401)
Listing Agent: Jc Sciara (941-725-7619)
© 2012 yellowkeyrealty.com, Inc. -
Policies | Articles
| All Counties
| Cities-For-Rent | Cities-For-Sale
Please select an email frequency other than None since you have chosen for us to
email you with changes that match your search.


text:
I have been a repeat customer of MJM for several years because of the wonderful service they provide. My reason I am taking the time to submit this...Read More ->
Most businesses have three things they can offer: price, product and service. It's rare that one business consistently offers all three. After more...Read More ->